MAM
‘Nazar’ fame Meera is Jolen brand Ambassador
BANGALORE: Mahesh Bhatt’s Nazar star, Pakistani actor Meera is the new brand ambassador for Jolen range of beauty products. Three ad films shot for television will unveil the range of Jolen products over the next few months.
“No budgets had been specifically earmarked for promotion. Depending on their experience this time around, ad budgets would be frozen. The focus would be A+ class, A class and B+ class cities, and initially regional channels would beam the ad clips,” says Kundan Care Products Ltd. DM Marketing Rakesh Bakshi. Kundan Care Products Ltd has been authorized to sell their products in India by Jolen Inc.
“The Cream Bleach market is sized around Rs.750 million currently. With the addition of Jolen we expect it to grow to around Rs.1 billion, and we should easily garner around 40% share of this market, since Jolen is a well-known, trusted brand and sold in more than 40 countries.
Besides the US and Germany we in India are the only company that will manufacture Jolen products. The prices will be quite competitive too, for example a 35-gram pack costs about US$4.95 (Rs.220/-). We will be able to offer it for Rs.89/-. Similarly, a 140 ms pack costs US$9,95 (Rs.440/-) which we will sell at Rs.220.” said Bakshi.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
